43 patents
Utility
Sustained Release Aminopyridine Composition
7 Dec 23
A pharmaceutical composition which comprises a therapeutically effective amount of a aminopyridine dispersed in a release matrix, including, for example, a composition that can be formulated into a stable, sustained-release oral dosage formulation, such as a tablet which provides, upon administration to a patient, a therapeutically effective plasma level of the aminopyridine for a period of at least 12 hours, preferably 24 hours or more and the use of the composition to treat various neurological diseases.
Andrew R. Blight, Ron Cohen
Filed: 23 Aug 23
Utility
Sustained Release Aminopyridine Composition
4 May 23
A pharmaceutical composition which comprises a therapeutically effective amount of a aminopyridine dispersed in a release matrix, including, for example, a composition that can be formulated into a stable, sustained-release oral dosage formulation, such as a tablet which provides, upon administration to a patient, a therapeutically effective plasma level of the aminopyridine for a period of at least 12 hours, preferably 24 hours or more and the use of the composition to treat various neurological diseases.
Andrew R. Blight, Ron Cohen
Filed: 29 Dec 22
Utility
Use of Neuregulin to Treat Peripheral Nerve Injury
20 Apr 23
The disclosure provides compositions and methods for preventing, ameliorating a sign or symptom of, or treating peripheral nerve injury.
Anthony O. Caggiano, Anthony J. Bella, Anindita Ganguly, Jennifer Iaci, Tom Parry, Raymond Warren Colburn
Filed: 28 Mar 22
Utility
Sustained Release Compositions of 4-AMINOPYRIDINE
13 Oct 22
The present invention generally relates to sustained release 4-aminopyridine tablets, which include a core and a coating.
Joseph E. Cobb, JR., Thomas B. Gold, Rohini D'Souza, Susan L. Way
Filed: 19 Nov 21
Utility
Sustained Release Aminopyridine Composition
22 Sep 22
A pharmaceutical composition which comprises a therapeutically effective amount of a aminopyridine dispersed in a release matrix, including, for example, a composition that can be formulated into a stable, sustained-release oral dosage formulation, such as a tablet which provides, upon administration to a patient, a therapeutically effective plasma level of the aminopyridine for a period of at least 12 hours, preferably 24 hours or more and the use of the composition to treat various neurological diseases.
Andrew R. Blight, Ron Cohen
Filed: 2 Jun 22
Utility
A2A Antagonists As Cognition and Motor Function Enhancers
28 Apr 22
Methods are described for inducing cognition and motor function enhancement in patients suffering from Parkinson's disease by administering an effective amount of an Adenosine 2a antagonist.
Stephen I. Bandak, Kevin J. Black, Meghan C. Campbell
Filed: 7 Jun 21
Utility
Methods for Treating Cancer Using Tozadenant
24 Mar 22
Provided herein are methods and compositions for treatment of patients with cancer using tozadenant.
Cory Kostrub
Filed: 19 Dec 19
Utility
Sustained Release Aminopyridine Composition
10 Feb 22
A pharmaceutical composition which comprises a therapeutically effective amount of a aminopyridine dispersed in a release matrix, including, for example, a composition that can be formulated into a stable, sustained-release oral dosage formulation, such as a tablet which provides, upon administration to a patient, a therapeutically effective plasma level of the aminopyridine for a period of at least 12 hours, preferably 24 hours or more and the use of the composition to treat various neurological diseases.
Andrew R. Blight, Ron Cohen
Filed: 26 Oct 21
Utility
Therapeutic dosing of a neuregulin or a subsequence thereof for treatment or prophylaxis of heart failure
1 Feb 22
The invention relates to treatment of heart failure in a mammal.
Anthony O. Caggiano, Anindita Ganguly, Jennifer Iaci, Tom Parry
Filed: 9 Sep 19
Utility
Sustained Release Compositions of 4-AMINOPYRIDINE
4 Nov 21
The present invention generally relates to sustained release 4-aminopyridine tablets, which include a core and a coating.
Joseph E. Cobb, JR., Thomas B. Gold, Rohini D'Souza, Susan L. Way
Filed: 13 Jul 21
Utility
Methods of reducing extravasation of inflammatory cells
12 Oct 21
A method for modifying access of cells to extravascular spaces and regions comprising administering to a patient an enzyme that cleaves chondroitin sulfate proteoglycans is provided.
Elliott A. Gruskin, Jack L. Tseng, Anthony O. Caggiano
Filed: 17 Jul 17
Utility
Carbonate prodrugs and methods of using the same
5 Oct 21
The present invention provides carbonate prodrugs which comprise a carbonic phosphoric anhydride prodrug moiety attached to the hydroxyl or carboxyl group of a parent drug moiety.
Naweed Muhammad, Keith R. Bley
Filed: 1 Jul 19
Utility
Methods of Using Sustained Release Aminopyridine Compositions
19 Aug 21
A pharmaceutical composition which comprises a therapeutically effective amount of a aminopyridine dispersed in a release matrix, including, for example, a composition that can be formulated into a stable, sustained-release oral dosage formulation, such as a tablet which provides, upon administration to a patient, a therapeutically effective plasma level of the aminopyridine for a period of at about 12 hours and the use of the composition to treat various neurological diseases, including multiple sclerosis.
Andrew R. Blight, Ron Cohen
Filed: 4 May 21
Utility
Methods for detecting cardiac damage
27 Jul 21
The present invention relates to a method for detecting heart damage in a patient.
Xinhua Yan, Anthony O. Caggiano
Filed: 20 Mar 19
Utility
Sustained Release Aminopyridine Composition
8 Jul 21
A pharmaceutical composition which comprises a therapeutically effective amount of a aminopyridine dispersed in a release matrix, including, for example, a composition that can be formulated into a stable, sustained-release oral dosage formulation, such as a tablet which provides, upon administration to a patient, a therapeutically effective plasma level of the aminopyridine for a period of at least 12 hours, preferably 24 hours or more and the use of the composition to treat various neurological diseases.
Andrew R. Blight, Ron Cohen
Filed: 16 Mar 21
Utility
Compositions and Methods for Treating Alzheimer's Disease and Parkinson's Disease
17 Jun 21
The present invention is directed to tablets for oral administration to a subject, comprising a therapeutically effective amount of SYN120 or a pharmaceutically acceptable salt thereof, wherein the tablet is substantially free of lactose.
Christopher G. SALENTINE, Thomas R. MALEFYT
Filed: 1 Mar 21
Utility
Water-soluble acetaminophen analogs
1 Jun 21
The present invention provides water-soluble acetaminophen prodrugs and formulations which may be suitable for parenteral administration.
Naweed Muhammad, Keith R. Bley
Filed: 9 Sep 19
Utility
Compositions and methods for treating Alzheimer's disease and Parkinson's disease
13 Apr 21
The present invention is directed to tablets for oral administration to a subject, comprising a therapeutically effective amount of SYN120 or a pharmaceutically acceptable salt thereof, wherein the tablet is substantially free of lactose.
Christopher G. Salentine, Thomas R. Malefyt
Filed: 16 Jan 19
Utility
Sustained Release Compositions of 4-AMINOPYRIDINE
25 Mar 21
The present invention generally relates to sustained release 4-aminopyridine tablets, which include a core and a coating.
Joseph E. Cobb, Jr., Thomas B. Gold, Rohini D'Souza, Susan L. Way
Filed: 4 Dec 20
Utility
Method for Achieving Desired Glial Growth Factor 2 Plasma Levels
4 Mar 21
The present invention relates to administering glial growth factor 2 (GGF2) to a patient in need thereof, to achieve serum levels of GGF2 within a desired therapeutic window determined based on the disease or disorder afflicting the patient.
Haesun Kim, Anthony O. Caggiano
Filed: 18 May 20